Study Comparing a Soybean Oil-Based With an Olive Oil-Based Lipid Emulsion in Healthy Volunteers and ICU Patients (TPN)
Recruitment status was Active, not recruiting
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
Many hospitalized patients who are malnourished or not eating receive intravenous feeding or total parenteral nutrition (TPN). Despite improving nutrition, TPN may increase the risk of infections and hospital complications. We do not know why TPN increases hospital complications, but it may be caused by the high sugar or fat content in TPN solutions.
| Condition | Intervention | Phase |
|---|---|---|
|
Parenteral Nutrition |
Drug: ClinOleic Drug: Intralipid |
Phase 2 Phase 3 |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Safety/Efficacy Study Intervention Model: Parallel Assignment Masking: Double Blind (Subject, Caregiver, Investigator) Primary Purpose: Treatment |
| Official Title: | Studies Comparing a Soybean Oil-Based vs Olive Oil-Based Lipid Emulsion: Effects on Endothelial Function, Inflammatory Markers, Oxidative Stress, Immune Function,Insulin Sensitivity and Carb Metabolism in Healthy Volunteers and ICU Pts |
- Immune function/nosocomial infection rate [ Time Frame: 2 years ] [ Designated as safety issue: Yes ]
- endothelial function [ Time Frame: 2-year ] [ Designated as safety issue: No ]
- inflammatory markers [ Time Frame: 2-year ] [ Designated as safety issue: No ]
- oxidative stress [ Time Frame: 2-year ] [ Designated as safety issue: No ]
- autonomic nervous system [ Time Frame: 2-year ] [ Designated as safety issue: No ]
- insulin sensitivity [ Time Frame: 2-year ] [ Designated as safety issue: No ]
- hospital mortality [ Time Frame: 2-year ] [ Designated as safety issue: Yes ]
| Estimated Enrollment: | 112 |
| Study Start Date: | November 2008 |
| Estimated Study Completion Date: | December 2010 |
| Estimated Primary Completion Date: | December 2010 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
Experimental: 1
TPN with Intralipid (30%)
|
Drug: Intralipid
TPN with Intralipid (30%)
|
|
Experimental: 2
TPN with ClinOleic (20%)
|
Drug: ClinOleic
TPN with ClinOleic (20%)
|
Detailed Description:
This study compares the effect of a soybean oil-based versus an olive oil-based lipid emulsion in healthy volunteers and in critically ill patients. In healthy volunteers, your blood sugar levels, blood vessel function, and your ability to fight infections will be examined. In ICU patients, we examines whether use of the olive oil-based lipid emulsion may decrease the risk of infection and hospital complications.
Eligibility| Ages Eligible for Study: | 18 Years to 80 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | Yes |
For the healthy volunteer study:
Inclusion Criteria:
- Healthy males or females, BMI 25 -35 kg/m2, between the ages of 18 and 65 years.
Exclusion Criteria:
- The patient is pregnant or breast feeding
- Subjects have or with history of diabetes, hypertension, fasting triglyceride levels > 250 mg/dL, liver disease (ALT 2.5x > upper limit of normal), serum creatinine ≥1.5 mg/dL
- Smokers or ex-smoker < 3 months of cessation, drug or alcohol abuse
- Mental condition rendering the subject unable to understand the scope and possible consequences of the study.
For the ICU study:
Inclusion criteria:
- Age: 18 - 80 years when initiating PN
- In medical/surgical ICU
- Has central venous access to administer PN
- Anticipated to receive PN ≥ 5 days
Exclusion criteria:
- Enrolled in an investigative study within the last 30 days prior to study entry
- Female patients: pregnant or breast feeding
- Has clinical sepsis (defined as mean arterial pressure (MAP) < 60 mmHg on ≥ 2 occasions and unstable BP despite pressor support) within 24 hours prior to study entry
- Has known cirrhosis or total bilirubin ≥ 10.0 mg/dL
- Has chronic renal failure (defined as requirement for hemodialysis or peritoneal dialysis therapy), or creatinine ≥ 3.5 mg/dL without CRRT, or requires acute post-operative dialysis
- Has an active malignancy (defined as requiring chemotherapy, radiation, and/or surgical intervention within 90 days prior to study entry) (excluding non-melanoma skin cancer)
- Has known AIDS
- Has a terminal illness (life expectancy < 7 days)
- Has undergone organ transplantation
- Has received PN with lipid within 48 hours prior to study entry
- Has mental disability to understand the scope and possible consequences of the study and the legally authorized representative is unavailable
- Has a baseline serum triglyceride > 400 mg/dL
Contacts and Locations| United States, Georgia | |
| Grady Memorial Hospital | |
| Atlanta, Georgia, United States, 30303 | |
| Emory University Hospital | |
| Atlanta, Georgia, United States, 30322 | |
| Principal Investigator: | Guillermo Umpierrez, MD | Emory University |
More Information
No publications provided by Emory University
Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
| Responsible Party: | Guillermo Umpierrez, MD, Emory University School of Medicine |
| ClinicalTrials.gov Identifier: | NCT00672854 History of Changes |
| Other Study ID Numbers: | e7543/e7587, TPN |
| Study First Received: | April 18, 2008 |
| Last Updated: | August 13, 2010 |
| Health Authority: | United States: Food and Drug Administration United States: Institutional Review Board |
Keywords provided by Emory University:
|
parenteral nutrition lipid emulsion nosocomial infection mortality endothelial function inflammatory markers |
oxidative stress immune function autonomic nervous system insulin sensitivity carbohydrate metabolism |
Additional relevant MeSH terms:
|
Insulin Resistance Hyperinsulinism Glucose Metabolism Disorders Metabolic Diseases |
ClinicalTrials.gov processed this record on May 19, 2013